NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Rhea-AI Summary
NeuroSense Therapeutics (NASDAQ: NRSN), a late-clinical stage biotech company focused on neurodegenerative diseases, has secured a $500,000 private placement from a single investor. The company will issue 333,334 ordinary shares at $1.50 per share, representing a significant 40% premium to the September 3, 2025 closing price.
The financing, expected to close on September 8, 2025, will provide working capital and serve as a bridge to upcoming milestones. CEO Alon Ben-Noon highlighted this as their third premium-to-market financing, emphasizing minimal shareholder dilution while strengthening the company's balance sheet.
Positive
- Shares priced at 40% premium to market, indicating investor confidence
- Third consecutive financing secured at above-market pricing
- Minimal shareholder dilution due to premium pricing
- Strategic bridge financing to support upcoming milestones
Negative
- Small financing amount of only $500,000 suggests limited runway extension
- Need for bridge financing may indicate cash constraints
- Reliance on private placements for funding could signal limited financing options
News Market Reaction – NRSN
In the Sep 4 session, NRSN gained 2.80%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.7% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Financing at
Under the terms of the agreement, NeuroSense will issue 333,334 ordinary shares at a purchase price of
Proceeds from the financing are expected to be used for general corporate purposes and working capital.
Alon Ben-Noon, CEO of NeuroSense, commented: "This ordinary share only investment serves as a short-term bridge as we continue to advance our activities and prepare for our next stage of growth. This is our third financing which is with private investors at a premium to market. This enables us to strengthen our balance sheet as the Company advances toward key upcoming milestones, while minimizing dilution for our shareholders."
The offering is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. The securities offered and sold in this transaction have not been registered under the Securities Act and may not be offered or sold in
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the offering, including as to the consummation of the offering described above, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the receipt of proceeds of the offering. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the offering as described above will not consummate or will be delayed, the risk of a delay in submission by the Company of its regulatory dossier, that regulatory approvals for PrimeC will be delayed or not obtained in
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-500-000-private-placement-at-premium-to-market-price-302546560.html
SOURCE NeuroSense